Discontinuation of primary prophylaxis against Mycobacterium avium complex infection in HIV-infected persons receiving antiretroviral therapy: observations from a large national cohort in the United States, 1992-2002.
In a large, diverse cohort of human immunodeficiency virus (HIV)-infected persons receiving routine care, the proportion of eligible persons who discontinued primary prophylaxis against Mycobacterium avium complex (MAC) infection, according to guidelines of the US Public Health Service and the Infectious Diseases Society of America, increased from 16.7% (in 1996) to 84.9% (in 2002). The discontinuation of primary prophylaxis was not associated with an increased risk of disseminated MAC infection.
Brooks
John T
JT
Epidemiology Branch, Division of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA. zud4@cdc.gov
Song
Ruiguang
R
Hanson
Debra L
DL
Wolfe
Mitchell
M
Swerdlow
David L
DL
D017088:AIDS-Related Opportunistic Infections / Q000453:epidemiology / Q000517:prevention & control*; D019072:Antibiotic Prophylaxis; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D015331:Cohort Studies; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D015270:Mycobacterium avium-intracellulare Infection / Q000453:epidemiology / Q000517:prevention & control*; D017410:Practice Guidelines as Topic; D014481:United States